Hildegarde Paz-Díaz

Pulmonary Rehabilitation Improves Depression, Anxiety, Dyspnea and Health Status in Patients with COPD

Hildegarde Paz-Díaz, María Montes de, José María Nebot López et al. · American Journal of Physical Medicine & Rehabilitation · 2006 · 209 citations

Medicine, Rehabilitation Medicine, Pulmonary Function Testing +16

Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD

Carlos Vassaux, Luis Torre‐Bouscoulet, Salah Zeineldine et al. · European Respiratory Journal · 2008 · 138 citations · Full text

Health Professions, Physiology, Exercise Testing +16

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Patrick A. Flume, Reta Fischer Biner, D.G. Downey et al. · The Lancet Respiratory Medicine · 2021 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for <i>F508del-CFTR</i>

Jonathan H. Rayment, Fadi Asfour, Margaret Rosenfeld et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 36 citations · Full text

Medicine, Pediatrics, Pharmacology +17

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

Gregory S. Sawicki, Mark Chilvers, John McNamara et al. · Journal of Cystic Fibrosis · 2022 · 13 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +16